| Original language | English (US) |
|---|---|
| Pages (from-to) | 89-96 |
| Number of pages | 8 |
| Journal | Progress in Cardiovascular Diseases |
| Volume | 36 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1993 |
| Externally published | Yes |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Progress in Cardiovascular Diseases, Vol. 36, No. 2, 1993, p. 89-96.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Developmental history, early use, and implementation of the automatic implantable cardioverter defibrillator
AU - Mower, Morton M.
AU - Hauser, Robert G.
N1 - Funding Information: tiveness against otherwise lethal arrhythmias (Fig 7). Questions have recently been raised that controlled trials were not done to absolutely confirm the value of the AICD; of course, it was difficult to find any investigators who were willing to randomize their postcardiac arrest patients for this purpose. Still these new criticisms are of major concern and may adversely affect, through overreaction of third party payers, how the therapy would otherwise be allowed to normally evolve. It is quite fortunate, however, that we are now in a period where there are a number of prospective trials of implantable defibrillator therapy which have been mounted for high-risk patients who are yet to have an initial serious arrhythmic event. These are very large-scale, expensive, multicenter prospective randomized studies whose results can hopefully be applied in retrospect to the present cardiac arrest populations now largely being treated.14,15 The first such prospective study is the Coronary Artery Bypass Graft-ICO (CABG patch) trial whose principal investigator is Thomas Bigger, MD of Columbia University. It is enrolling high-risk coronary artery disease patients who have not had a previous cardiac arrest, but who need revascularization. All patients will be revascularized, and half randomized to AICD as well. The enrollment in this trial has been excellent and it has received a very favorably evaluation for funding by the National Institutes of Health. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1993
Y1 - 1993
UR - http://www.scopus.com/inward/record.url?scp=0027670860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027670860&partnerID=8YFLogxK
U2 - 10.1016/0033-0620(93)90002-U
DO - 10.1016/0033-0620(93)90002-U
M3 - Article
C2 - 8367610
AN - SCOPUS:0027670860
SN - 0033-0620
VL - 36
SP - 89
EP - 96
JO - Progress in Cardiovascular Diseases
JF - Progress in Cardiovascular Diseases
IS - 2
ER -